CN101594789A - 益生菌(婴儿)食品 - Google Patents
益生菌(婴儿)食品 Download PDFInfo
- Publication number
- CN101594789A CN101594789A CNA2007800417554A CN200780041755A CN101594789A CN 101594789 A CN101594789 A CN 101594789A CN A2007800417554 A CNA2007800417554 A CN A2007800417554A CN 200780041755 A CN200780041755 A CN 200780041755A CN 101594789 A CN101594789 A CN 101594789A
- Authority
- CN
- China
- Prior art keywords
- composition
- food
- children
- acid
- atcc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 235000013305 food Nutrition 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 claims abstract description 89
- 241000186605 Lactobacillus paracasei Species 0.000 claims abstract description 24
- 230000001580 bacterial effect Effects 0.000 claims abstract description 24
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 claims abstract description 22
- 229940009289 bifidobacterium lactis Drugs 0.000 claims abstract description 19
- 235000008452 baby food Nutrition 0.000 claims abstract description 15
- 150000002632 lipids Chemical class 0.000 claims abstract description 13
- 150000001720 carbohydrates Chemical class 0.000 claims abstract description 12
- 235000013373 food additive Nutrition 0.000 claims abstract description 11
- 239000002778 food additive Substances 0.000 claims abstract description 11
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 10
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 10
- 244000199866 Lactobacillus casei Species 0.000 claims abstract 2
- 239000000413 hydrolysate Substances 0.000 claims description 31
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 claims description 26
- 208000026935 allergic disease Diseases 0.000 claims description 24
- 206010020751 Hypersensitivity Diseases 0.000 claims description 23
- 230000007815 allergy Effects 0.000 claims description 23
- 208000015181 infectious disease Diseases 0.000 claims description 20
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 18
- 210000000936 intestine Anatomy 0.000 claims description 18
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 235000021342 arachidonic acid Nutrition 0.000 claims description 13
- 229940114079 arachidonic acid Drugs 0.000 claims description 13
- RLCKHJSFHOZMDR-UHFFFAOYSA-N (3R, 7R, 11R)-1-Phytanoid acid Natural products CC(C)CCCC(C)CCCC(C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-UHFFFAOYSA-N 0.000 claims description 11
- RLCKHJSFHOZMDR-PWCSWUJKSA-N 3,7R,11R,15-tetramethyl-hexadecanoic acid Chemical compound CC(C)CCC[C@@H](C)CCC[C@@H](C)CCCC(C)CC(O)=O RLCKHJSFHOZMDR-PWCSWUJKSA-N 0.000 claims description 11
- 241000282849 Ruminantia Species 0.000 claims description 11
- 235000014633 carbohydrates Nutrition 0.000 claims description 11
- 230000007062 hydrolysis Effects 0.000 claims description 11
- 238000006460 hydrolysis reaction Methods 0.000 claims description 11
- 102000004407 Lactalbumin Human genes 0.000 claims description 10
- 108090000942 Lactalbumin Proteins 0.000 claims description 10
- 235000013406 prebiotics Nutrition 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 9
- 229910021529 ammonia Inorganic materials 0.000 claims description 9
- 239000000047 product Substances 0.000 claims description 9
- 235000018102 proteins Nutrition 0.000 claims description 9
- 208000005587 Refsum Disease Diseases 0.000 claims description 8
- 208000030597 adult Refsum disease Diseases 0.000 claims description 8
- 230000002265 prevention Effects 0.000 claims description 8
- 230000007774 longterm Effects 0.000 claims description 7
- 229920001542 oligosaccharide Polymers 0.000 claims description 7
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 7
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 6
- 108010011756 Milk Proteins Proteins 0.000 claims description 6
- 102000014171 Milk Proteins Human genes 0.000 claims description 6
- 235000019197 fats Nutrition 0.000 claims description 6
- 239000008103 glucose Substances 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 210000002784 stomach Anatomy 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 239000004475 Arginine Substances 0.000 claims description 5
- 108010076119 Caseins Proteins 0.000 claims description 5
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
- 239000005018 casein Substances 0.000 claims description 5
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 claims description 5
- 235000021240 caseins Nutrition 0.000 claims description 5
- 239000002773 nucleotide Substances 0.000 claims description 5
- 125000003729 nucleotide group Chemical group 0.000 claims description 5
- 239000003531 protein hydrolysate Substances 0.000 claims description 5
- 125000001931 aliphatic group Chemical group 0.000 claims description 4
- JAZBEHYOTPTENJ-JLNKQSITSA-N all-cis-5,8,11,14,17-icosapentaenoic acid Chemical compound CC\C=C/C\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O JAZBEHYOTPTENJ-JLNKQSITSA-N 0.000 claims description 4
- 235000020673 eicosapentaenoic acid Nutrition 0.000 claims description 4
- 229960005135 eicosapentaenoic acid Drugs 0.000 claims description 4
- JAZBEHYOTPTENJ-UHFFFAOYSA-N eicosapentaenoic acid Natural products CCC=CCC=CCC=CCC=CCC=CCCCC(O)=O JAZBEHYOTPTENJ-UHFFFAOYSA-N 0.000 claims description 4
- 210000001508 eye Anatomy 0.000 claims description 4
- -1 fucose oligosaccharides Chemical class 0.000 claims description 4
- 210000004392 genitalia Anatomy 0.000 claims description 4
- IJTNSXPMYKJZPR-UHFFFAOYSA-N parinaric acid Chemical compound CCC=CC=CC=CC=CCCCCCCCC(O)=O IJTNSXPMYKJZPR-UHFFFAOYSA-N 0.000 claims description 4
- 230000002485 urinary effect Effects 0.000 claims description 4
- OIZGSVFYNBZVIK-FHHHURIISA-N 3'-sialyllactose Chemical compound O1[C@@H]([C@H](O)[C@H](O)CO)[C@H](NC(=O)C)[C@@H](O)C[C@@]1(C(O)=O)O[C@@H]1[C@@H](O)[C@H](O[C@H]([C@H](O)CO)[C@H](O)[C@@H](O)C=O)O[C@H](CO)[C@@H]1O OIZGSVFYNBZVIK-FHHHURIISA-N 0.000 claims description 3
- 208000016097 disease of metabolism Diseases 0.000 claims description 3
- 235000004213 low-fat Nutrition 0.000 claims description 3
- 208000030159 metabolic disease Diseases 0.000 claims description 3
- 235000021239 milk protein Nutrition 0.000 claims description 3
- 239000000126 substance Substances 0.000 claims description 3
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 claims description 2
- PIFPCDRPHCQLSJ-WYIJOVFWSA-N 4,8,12,15,19-Docosapentaenoic acid Chemical compound CC\C=C\CC\C=C\C\C=C\CC\C=C\CC\C=C\CCC(O)=O PIFPCDRPHCQLSJ-WYIJOVFWSA-N 0.000 claims description 2
- 240000008886 Ceratonia siliqua Species 0.000 claims description 2
- 235000013912 Ceratonia siliqua Nutrition 0.000 claims description 2
- PIFPCDRPHCQLSJ-UHFFFAOYSA-N Clupanodonic acid Natural products CCC=CCCC=CCC=CCCC=CCCC=CCCC(O)=O PIFPCDRPHCQLSJ-UHFFFAOYSA-N 0.000 claims description 2
- 208000035473 Communicable disease Diseases 0.000 claims description 2
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 claims description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 claims description 2
- PNNNRSAQSRJVSB-SLPGGIOYSA-N Fucose Natural products C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C=O PNNNRSAQSRJVSB-SLPGGIOYSA-N 0.000 claims description 2
- 229920001202 Inulin Polymers 0.000 claims description 2
- 102100033663 Transforming growth factor beta receptor type 3 Human genes 0.000 claims description 2
- IJTNSXPMYKJZPR-WVRBZULHSA-N alpha-parinaric acid Natural products CCC=C/C=C/C=C/C=CCCCCCCCC(=O)O IJTNSXPMYKJZPR-WVRBZULHSA-N 0.000 claims description 2
- 108010079292 betaglycan Proteins 0.000 claims description 2
- 238000006471 dimerization reaction Methods 0.000 claims description 2
- 150000002148 esters Chemical class 0.000 claims description 2
- 235000013312 flour Nutrition 0.000 claims description 2
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 2
- 229940029339 inulin Drugs 0.000 claims description 2
- 235000021290 n-3 DPA Nutrition 0.000 claims description 2
- 229920001206 natural gum Polymers 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 claims description 2
- 150000003839 salts Chemical class 0.000 claims description 2
- 150000003408 sphingolipids Chemical class 0.000 claims description 2
- 150000003626 triacylglycerols Chemical class 0.000 claims description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical class OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims 2
- 239000005862 Whey Substances 0.000 claims 2
- 102000007544 Whey Proteins Human genes 0.000 claims 2
- 108010046377 Whey Proteins Proteins 0.000 claims 2
- 102000010445 Lactoferrin Human genes 0.000 claims 1
- 108010063045 Lactoferrin Proteins 0.000 claims 1
- 238000010612 desalination reaction Methods 0.000 claims 1
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims 1
- 235000021242 lactoferrin Nutrition 0.000 claims 1
- 229940078795 lactoferrin Drugs 0.000 claims 1
- 235000020183 skimmed milk Nutrition 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 12
- 201000010099 disease Diseases 0.000 abstract description 11
- 244000052769 pathogen Species 0.000 abstract description 3
- 230000001717 pathogenic effect Effects 0.000 abstract description 3
- 239000006041 probiotic Substances 0.000 description 16
- 235000018291 probiotics Nutrition 0.000 description 16
- 208000024891 symptom Diseases 0.000 description 14
- 208000010668 atopic eczema Diseases 0.000 description 12
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 12
- 235000020247 cow milk Nutrition 0.000 description 11
- 235000001014 amino acid Nutrition 0.000 description 10
- 150000001413 amino acids Chemical class 0.000 description 10
- 230000000694 effects Effects 0.000 description 10
- 230000000529 probiotic effect Effects 0.000 description 10
- 230000000172 allergic effect Effects 0.000 description 9
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 8
- 206010012735 Diarrhoea Diseases 0.000 description 6
- 206010065042 Immune reconstitution inflammatory syndrome Diseases 0.000 description 6
- 208000008498 Infantile Refsum disease Diseases 0.000 description 6
- 229920002774 Maltodextrin Polymers 0.000 description 6
- 239000005913 Maltodextrin Substances 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 6
- 230000000774 hypoallergenic effect Effects 0.000 description 6
- 239000004310 lactic acid Substances 0.000 description 6
- 235000014655 lactic acid Nutrition 0.000 description 6
- 229940035034 maltodextrin Drugs 0.000 description 6
- 244000005700 microbiome Species 0.000 description 6
- 241001134770 Bifidobacterium animalis Species 0.000 description 5
- 201000010859 Milk allergy Diseases 0.000 description 5
- 229940118852 bifidobacterium animalis Drugs 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 235000016709 nutrition Nutrition 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 241000186000 Bifidobacterium Species 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
- 206010061218 Inflammation Diseases 0.000 description 4
- 208000009793 Milk Hypersensitivity Diseases 0.000 description 4
- 108010009736 Protein Hydrolysates Proteins 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000010521 absorption reaction Methods 0.000 description 4
- 235000009697 arginine Nutrition 0.000 description 4
- 239000004202 carbamide Substances 0.000 description 4
- 235000013351 cheese Nutrition 0.000 description 4
- 230000004054 inflammatory process Effects 0.000 description 4
- 210000002824 peroxisome Anatomy 0.000 description 4
- 239000002689 soil Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 208000000059 Dyspnea Diseases 0.000 description 3
- 206010013975 Dyspnoeas Diseases 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 description 3
- 206010016946 Food allergy Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 208000005141 Otitis Diseases 0.000 description 3
- 201000009840 acute diarrhea Diseases 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- 235000006708 antioxidants Nutrition 0.000 description 3
- 208000006673 asthma Diseases 0.000 description 3
- 206010006451 bronchitis Diseases 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000002349 favourable effect Effects 0.000 description 3
- 235000020932 food allergy Nutrition 0.000 description 3
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 3
- 235000004554 glutamine Nutrition 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 230000035945 sensitivity Effects 0.000 description 3
- 239000006188 syrup Substances 0.000 description 3
- 235000020357 syrup Nutrition 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
- LRFVTYWOQMYALW-UHFFFAOYSA-N 9H-xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 201000004624 Dermatitis Diseases 0.000 description 2
- 206010014561 Emphysema Diseases 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- ISAKRJDGNUQOIC-UHFFFAOYSA-N Uracil Chemical compound O=C1C=CNC(=O)N1 ISAKRJDGNUQOIC-UHFFFAOYSA-N 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000000890 antigenic effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 229910002092 carbon dioxide Inorganic materials 0.000 description 2
- 108010079058 casein hydrolysate Proteins 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 208000019902 chronic diarrheal disease Diseases 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 208000019258 ear infection Diseases 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 235000013922 glutamic acid Nutrition 0.000 description 2
- 239000004220 glutamic acid Substances 0.000 description 2
- UYTPUPDQBNUYGX-UHFFFAOYSA-N guanine Chemical compound O=C1NC(N)=NC2=C1N=CN2 UYTPUPDQBNUYGX-UHFFFAOYSA-N 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 229910052500 inorganic mineral Inorganic materials 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 210000004086 maxillary sinus Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 239000011707 mineral Substances 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- 210000000214 mouth Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 201000009240 nasopharyngitis Diseases 0.000 description 2
- 210000003695 paranasal sinus Anatomy 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- NHZMQXZHNVQTQA-UHFFFAOYSA-N pyridoxamine Chemical compound CC1=NC=C(CO)C(CN)=C1O NHZMQXZHNVQTQA-UHFFFAOYSA-N 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 210000003491 skin Anatomy 0.000 description 2
- 206010040872 skin infection Diseases 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N tryptophan Chemical compound C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 230000004143 urea cycle Effects 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 150000003722 vitamin derivatives Chemical class 0.000 description 2
- PHIQHXFUZVPYII-ZCFIWIBFSA-N (R)-carnitine Chemical compound C[N+](C)(C)C[C@H](O)CC([O-])=O PHIQHXFUZVPYII-ZCFIWIBFSA-N 0.000 description 1
- 208000004998 Abdominal Pain Diseases 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 208000008035 Back Pain Diseases 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 241001112696 Clostridia Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 206010011703 Cyanosis Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010052804 Drug tolerance Diseases 0.000 description 1
- 208000036649 Dysbacteriosis Diseases 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 208000001860 Eye Infections Diseases 0.000 description 1
- 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 description 1
- 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 150000008575 L-amino acids Chemical class 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
- 229930064664 L-arginine Natural products 0.000 description 1
- 235000014852 L-arginine Nutrition 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 1
- LEVWYRKDKASIDU-IMJSIDKUSA-N L-cystine Chemical compound [O-]C(=O)[C@@H]([NH3+])CSSC[C@H]([NH3+])C([O-])=O LEVWYRKDKASIDU-IMJSIDKUSA-N 0.000 description 1
- 239000004158 L-cystine Substances 0.000 description 1
- 235000019393 L-cystine Nutrition 0.000 description 1
- SHZGCJCMOBCMKK-DHVFOXMCSA-N L-fucopyranose Chemical compound C[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@@H]1O SHZGCJCMOBCMKK-DHVFOXMCSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 208000019693 Lung disease Diseases 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- JEVVKJMRZMXFBT-XWDZUXABSA-N Lycophyll Natural products OC/C(=C/CC/C(=C\C=C\C(=C/C=C/C(=C\C=C\C=C(/C=C/C=C(\C=C\C=C(/CC/C=C(/CO)\C)\C)/C)\C)/C)\C)/C)/C JEVVKJMRZMXFBT-XWDZUXABSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 208000001132 Osteoporosis Diseases 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 241000709664 Picornaviridae Species 0.000 description 1
- 206010035742 Pneumonitis Diseases 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N Retinaldehyde Chemical compound O=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 208000007014 Retinitis pigmentosa Diseases 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 210000000662 T-lymphocyte subset Anatomy 0.000 description 1
- 210000000447 Th1 cell Anatomy 0.000 description 1
- 210000004241 Th2 cell Anatomy 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- LPQOADBMXVRBNX-UHFFFAOYSA-N ac1ldcw0 Chemical compound Cl.C1CN(C)CCN1C1=C(F)C=C2C(=O)C(C(O)=O)=CN3CCSC1=C32 LPQOADBMXVRBNX-UHFFFAOYSA-N 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 208000037883 airway inflammation Diseases 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 230000002009 allergenic effect Effects 0.000 description 1
- 230000037354 amino acid metabolism Effects 0.000 description 1
- 229960004050 aminobenzoic acid Drugs 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 150000001615 biotins Chemical class 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229960004203 carnitine Drugs 0.000 description 1
- 229940071162 caseinate Drugs 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000013872 defecation Effects 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 235000021245 dietary protein Nutrition 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000007071 enzymatic hydrolysis Effects 0.000 description 1
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 1
- 208000011323 eye infectious disease Diseases 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 235000004280 healthy diet Nutrition 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 235000020256 human milk Nutrition 0.000 description 1
- 210000004251 human milk Anatomy 0.000 description 1
- 150000002460 imidazoles Chemical class 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 235000021125 infant nutrition Nutrition 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 230000000977 initiatory effect Effects 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 230000000366 juvenile effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000020978 long-chain polyunsaturated fatty acids Nutrition 0.000 description 1
- 235000012680 lutein Nutrition 0.000 description 1
- 229960005375 lutein Drugs 0.000 description 1
- 239000001656 lutein Substances 0.000 description 1
- KBPHJBAIARWVSC-RGZFRNHPSA-N lutein Chemical compound C([C@H](O)CC=1C)C(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\[C@H]1C(C)=C[C@H](O)CC1(C)C KBPHJBAIARWVSC-RGZFRNHPSA-N 0.000 description 1
- ORAKUVXRZWMARG-WZLJTJAWSA-N lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C ORAKUVXRZWMARG-WZLJTJAWSA-N 0.000 description 1
- 235000012661 lycopene Nutrition 0.000 description 1
- 229960004999 lycopene Drugs 0.000 description 1
- 239000001751 lycopene Substances 0.000 description 1
- OAIJSZIZWZSQBC-GYZMGTAESA-N lycopene Chemical compound CC(C)=CCC\C(C)=C\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C=C(/C)CCC=C(C)C OAIJSZIZWZSQBC-GYZMGTAESA-N 0.000 description 1
- 230000000527 lymphocytic effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 235000021243 milk fat Nutrition 0.000 description 1
- 230000000116 mitigating effect Effects 0.000 description 1
- 230000004682 mucosal barrier function Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 210000004126 nerve fiber Anatomy 0.000 description 1
- 150000002814 niacins Chemical class 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000003071 parasitic effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 229920000768 polyamine Polymers 0.000 description 1
- 230000001902 propagating effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000007026 protein scission Effects 0.000 description 1
- 235000008151 pyridoxamine Nutrition 0.000 description 1
- 239000011699 pyridoxamine Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 235000019192 riboflavin Nutrition 0.000 description 1
- 239000002151 riboflavin Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 238000009938 salting Methods 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 210000003718 sphenoid sinus Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 229960000344 thiamine hydrochloride Drugs 0.000 description 1
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 1
- 239000011747 thiamine hydrochloride Substances 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- ZCIHMQAPACOQHT-ZGMPDRQDSA-N trans-isorenieratene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/c1c(C)ccc(C)c1C)C=CC=C(/C)C=Cc2c(C)ccc(C)c2C ZCIHMQAPACOQHT-ZGMPDRQDSA-N 0.000 description 1
- KBPHJBAIARWVSC-XQIHNALSSA-N trans-lutein Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C(=CC(O)CC2(C)C)C KBPHJBAIARWVSC-XQIHNALSSA-N 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
- 229940035893 uracil Drugs 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
- FJHBOVDFOQMZRV-XQIHNALSSA-N xanthophyll Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CC(O)CC1(C)C)C=CC=C(/C)C=CC2C=C(C)C(O)CC2(C)C FJHBOVDFOQMZRV-XQIHNALSSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
- A23V2400/165—Paracasei
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/21—Streptococcus, lactococcus
- A23V2400/249—Thermophilus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/51—Bifidobacterium
- A23V2400/531—Lactis
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Pediatric Medicine (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Dairy Products (AREA)
Abstract
本发明涉及食品,如婴儿和儿童食品和用于婴儿和儿童的食品添加物。本发明提供一种包含脂质来源、碳水化合物来源和蛋白质来源的组合物,其特征在于组合物还包含保藏号为ATCC 27536的乳双歧杆菌(B.lactis)菌株和保藏号为ATCC 55544的类干酪乳杆菌(L.casei)菌株。所述组合物促进一般抗性,特别针对不希望有的病原体的传代和呼吸性疾病在儿童中的发病率。
Description
本发明涉及食品组合物,如婴儿食品和适用于儿童的食品添加物。尤其是,本发明涉及的配方可长期使用,适合于对反刍动物乳成分过敏(如具有牛乳变态反应的婴儿和儿童)或具有增加的发展所述敏感性危险的婴儿或儿童。本发明还涉及对一般抗性有积极贡献的配方,尤其是针对婴儿和儿童中的呼吸道感染。
在荷兰,用牛乳喂养的婴儿中2-3%发展成对牛乳蛋白的变态反应。牛乳变态反应产生的根本原因是遗传和环境的综合因素。来自有变态反应性疾病如哮喘、异位性湿疹、枯草热和/或食物变态反应发生的家族的儿童具有发展成牛乳变态反应的较高危险。通常,婴儿在出生后对食物蛋白形成耐受力。人们发现在有牛乳变态反应的婴儿中还没有形成良好的建立机制。
除遗传之外,其他因素也扮演了重要的角色。因此,在婴儿时期蛋白质的消化能力还没有达到最佳。这是由胃中相对低水平的蛋白质裂解酶和相对高pH引起的。此外,肠通常还增加渗透性,以致蛋白质分子能够通过肠壁并于再吸收后被认为是异质的。这些因素说明牛乳变态反应在婴儿时期相对广泛流行。
此外,人们发现在免疫系统的发育和成熟过程中,由微生物引起的刺激在生命的第一年中具有重要的作用。在无变态反应儿童的粪便中含有比变态反应儿童更多的双歧杆菌(bifidobacteria)和较少的梭菌(clostridia)。值得注意的是,肠菌群方面的变化在变态反应症状发展之前,这就暗示肠菌群的组成可能影响变态反应发展(的风险)。
在儿童中,牛乳变态反应的症状一般显现在皮肤、胃肠道以及呼吸道。这些症状都没有明确的针对或特异于牛乳变态反应,这就导致了诊断困难。在幼年儿童中的最大共同症状是腹泻、食物问题(如饮用困难)、呕吐、急腹痛、湿疹、荨麻疹、呼吸困难、咳嗽或在进食后喘气。
有阳性家族病史的婴儿推荐进行预防:这些是其父母、兄弟或姐妹证实患有牛乳变态反应的婴儿。到目前为止,对有阳性家族病史的儿童而言,建议饮食以部分或大量乳蛋白水解产物为基础;抗原性的蛋白表位已经被部分破坏(部分水解产物)或实际上完全由酶处理(彻底水解产物)。
已知的牛乳蛋白水解产物是乳清蛋白和酪蛋白水解产物。对于用于对反刍动物乳脂肪过敏的儿童,例如婴儿雷弗素姆病(IRD)患者,优选使用的是包含低乳脂含量起始原料的乳蛋白,如酪蛋白或酪蛋白酸盐。
深度水解(extensively hydrolyzed)乳蛋白产品,还被认为是第一代产品,主要包含分子量小于1500道尔顿的肽。人们发现,其有利于变应原性的极大降低。以大量酪蛋白水解产物为基础的食物证实对反刍动物蛋白质敏感的儿童有良好作用。例如,关于所述低变应原性产品的安全性,申请人公开了基于对牛乳变态反应儿童的双盲研究法,(已知的商标名为Frisolac(Terheggen-Lagro等.BMC Pediatrics(BMC儿科)(2002),2:10)。
尽管产品对目标群而言是安全的,但它仍然有许多缺点,特别是其需要长期使用如至少使用几个月才能显效。因而,血液里存在较高浓度的尿素,是氨基酸代谢超负荷的一种迹象。与脂肪酸和葡萄糖形成对比的是,氨基酸不能贮存。氨基酸也不能被分泌。在蛋白质(氨基酸)的新陈代谢中,二氧化碳和氨被释放。尿素循环从氨和二氧化碳中产生尿素,并且允许过量氮以无毒且易溶解的形式通过尿以尿素的形式排泄。
此外,大量的水解产物没有或只有非常低的诱导(口腔的)乳蛋白耐受性的能力(参见JP-03-181681;EP 629350;Schmidt等,Intestinal Immunology and FoodAllergy(肠免疫学和食品变态反应),34th NestléNutrition Workshop(营养研讨会),24-28页)。口腔耐受性的发展可能与所谓的肠壁紧密连接以延迟方式闭合和/或未及时闭合,以及相关的肠壁对变应原的渗透性相关。
尤其对于儿童,并且对于少年、成年人和老年人(男性和女性)来说重要的是通过健康的饮食增强一般抗性。特别是关于病原体穿过肠壁的风险,和关于对发生的胃肠道症状和呼吸性疾病,以及各种感染,如眼睛感染、皮肤感染、耳朵感染和/或耳朵炎症,以及皮肤、内和/或外生殖器和泌尿系统感染的增加抗性更是如此。
微生物穿过肠壁传播不仅意味着在血液中感染,也被称为脓毒症,而且通过肠壁传播后,感染可能引发脑膜炎,或体液中其他种类的感染。
胃肠道感染包含肠胃炎,其特征为胃、肠粘膜感染和/或炎症,急性和慢性腹泻。急性腹泻的特征为突然出现背离一般的排便模式,即排便频率以及粪便数量增加且粪便比平常包含更多水分,对个人而言最长持续时间达14天。慢性腹泻具有急性腹泻的症状,而且通常持续时间比14天更长。要理解胃肠症状还意味着腹痛、绞痛和特殊的疾病诸如例如幽门螺杆菌(Helicobacter pylori)感染。
呼吸性疾病包括涉及由(尤其是)细菌或病毒(尤其是普通感冒和流行性感冒病毒)感染或它们联合引起的小气道炎症(支气管炎)的感染。要理解这还意味着:由A、B或C型流感(病毒)引起的流行性感冒:传染性病毒引起的传染性疾病,其常常以流行病的形式出现。其他的实例有由于各种微生物引起的严重的肺组织炎症,以及局限性肺炎,通常用于形容轻度肺炎阶段的术语。这些炎症往往能由急性,高烧,胸腔、侧面和/或背部疼痛,冷颤,呼吸苦难,呕痰,由于缺氧导致的白色-带青色的皮肤又称发绀,以及鼻孔呼吸鉴定出。尤其后者发生在儿童中。要理解呼吸性疾病还指气管的疾病或感染,又称气管炎。还包括由于气管通道的收缩导致呼吸变得更加困难,和感染、梗阻、和过量难以排出的肺部粘液可能引发(非常严重的)呼吸困难。此外,这还包括普通感冒,其实际上是一种头部的鼻腔和咽和/或鼻旁窦(上颌窦和窦腔)的粘膜炎症,特别是由小核糖核酸病毒所引起的,以及与CNSLD(慢性非特异性肺病)相关的疾病如哮喘、慢性支气管炎和肺气肿。哮喘的特点在于周期性发生呼吸困难时期,伴随着艰难的呼气且往往在幼年时期就已经显现。慢性支气管炎是一种出现有规律咳嗽和/或呕出粘液并伴随着肺气肿、肺泡组织弹性降低症状的疾病。由于工业造成的大气污染的结果,并且由于气管频繁的感染以及主动/被动的吸烟,尤其是后者疾病会在较晚的时期显现。实际上,上述表明:身体上或身体内的所有部位可发生天然存在的无害微生物区系的不平衡。这种不平衡可能以天然存在的微生物区系变化的结果发生或作为从身体外部受到感染的结果发生。这通常涉及疾病,为了变得健康或免于感染或再次不平衡,机体需要免疫学上的抗性。气道疾病还被理解为指鼻窦炎。这是一种鼻旁窦炎症,包括窦腔、上颌窦、蝶窦和眼睛中间的筛状细胞。在上文中所描述的气道、胃肠道、皮肤、眼睛、内和/或外生殖器、泌尿系统和耳朵的感染可能是由细菌的、病毒的、寄生虫的或真菌起源的致病微生物所引起的。
本发明预计提供一种食品,尤其是儿童食品,其不会出现上述一种或多种缺点。本发明目的尤其在于提供一种最适食品,其适于对反刍动物乳蛋白过敏的儿童长期使用,或该最优食品适合于具有增加的发展该敏感性危险的婴儿和儿童预防性长期使用。此外,该食品优选适用于对反刍动物乳脂过敏的婴儿和儿童,如患有IRD的儿童。更具体地说,本发明的目的在于加强婴儿、儿童、少年、成年人和老年人的一般抗性。尤其是,本发明的目的在于通过食物的方式,降低在上文中所描述的呼吸性疾病和其他感染的危险,尤其针对婴儿和儿童,还有少年、成年人以及老年人。
申请人发现在食品中添加益生菌特定组合至少部分地消除上述缺陷,且长期食用该食品能够提高所述结果。
因此本发明提供一种适合作为儿童食品或(治疗的)食品添加物的食品组合物,其包含脂质来源、碳水化合物来源和含有最高3000道尔顿肽的低-变应原的酪蛋白水解产物,其特征在于该组合物还包含保藏号为ATCC 27536的乳双歧杆菌(B.lactis)菌株和保藏号为ATCC 55544的类干酪乳杆菌(L.easel)菌株。所述酪蛋白水解产物,例如是一种非变应原性的低脂的深度水解的酪蛋白水解产物。
本发明人意外地发现在婴儿营养品中,这些乳双歧杆菌和类干酪乳杆菌菌株独特的组合对儿童一般抗性、免疫体质和呼吸性疾病的发病率具有有利的影响。实际上,这种发病率可能达到70%或甚至更高。更特别地是,据观察,服用包含上述益生菌组合的食品组合物(配方)的儿童与食用同样配方但不含益生菌的儿童相比,气道感染的发病率减少。
因此,本发明还提供一种食品组合物,该组合物包含脂质来源、碳水化合物来源和蛋白质源,同时其还包含保藏号为ATCC 27536的乳双歧杆菌菌株和保藏号为ATCC 55544的类干酪乳杆菌菌株,条件是所述蛋白质来源为含有最高3000道尔顿的肽的无,低变应原性酪蛋白水解产物。其是例如这样的儿童食品,其本身已知以(部分水解的)乳牛的乳蛋白为基础,如酪蛋白、乳清蛋白或它们的混合物,并且以植物蛋白如来自谷类和豆类的蛋白质为基础,所述儿童食品至少补充有上述涉及的益生菌特定组合。
因此,本发明提供一种低变应原的食品和一种标准化食品。所述的食品组合物适于预防和治疗使用。
保藏号为ATCC 55544的类干酪乳杆菌类干酪亚种菌株(L.paracasei strain ssp.Paracasei)也是已知的,其制造商为Chr.Hansen,商品号为CRL 431。
已经发现,双歧杆菌适于减少氨负荷,特别是动物双歧杆菌乳亚种(Bifidobacterium animalis,ssp.Lactis),保藏号为ATCC 27536(乳双歧杆菌27536)。后者由Chr.Hansen制造,商品号为BB12。体外分析表明BB12菌株显示内皮细胞生长因子B在树突细胞中表达增加。本发明人认为该菌株对改善或修复肠壁的屏障功能是有利的。
对婴儿施用12个月的ATCC 55544和ATCC 27536的组合,导致特异性T-细胞亚型,即CD3+和CD3+CD4+群体的改变。
并不希望受限于任何理论,本发明人认为,在儿童中观察到的对不希望受到的感染的抵抗力增强是由益生菌菌株类干酪乳杆菌CRL431和乳双歧杆菌BB-12在胃肠道、粘膜屏障和气道中水平的联合效应导致的。
除能减少身体氨负荷的益生菌菌株外,该组合物还可包含其他组分,其能促进过量氨如氨基酸精氨酸的处理,从而在尿素循环中具有重要作用。
本发明组合物中益生菌的量可以变化,并且可取决于预计使用的益生菌种类和/或该组合物所需性质。优选地,该组合物包含至少103,优选103-109,如106-107菌落形成单位(cfu)/克产乳酸益生菌菌株。该组合物包含,如106-108个菌落形成单位的类干酪乳杆菌(L.paracasei)ATCC-55544和106-108个菌落形成单位的乳双歧杆菌ATCC-27536/克。上述菌株之间的相对比率,如10∶1-1∶10,优选5∶1-1∶5,如2∶1-1∶2。每株菌株的量大约相等的混合物获得好的效果。
根据本发明所述的组合物优选地包含至少一种组分,其对存在于该组合物中的一种或多种益生菌具有益生元作用。适宜益生元的实例有短链或长链果糖-寡糖和/或半乳糖-寡糖、菊粉、含岩藻糖的寡糖、β聚糖、角豆粉、树胶、果胶、唾液酸寡糖、唾液酸乳糖、短链或长链半乳聚糖和核苷酸。
令人惊讶地是,本发明所述组合物中的低-变应原的蛋白质水解产物还被发现能够刺激肠道中产乳酸益生菌菌株的生长。因此,该水解产物具有营养和益生元的作用。
由于口服摄入包含上述益生菌的组合物和来自低变应原蛋白质水解产物的肽的益生元效果,在具有牛乳蛋白变态反应的儿童肠菌群中的不平衡可以至少部分被修复。
低-变应原的酪蛋白水解产物优选为低-脂的。其优选主要包含具有低于1500道尔顿分子量的肽。尤其合适的是包含至少约80mol%最多3个氨基酸的肽和/或不包含长度超过6个氨基酸的肽的水解产物。分子量小于0.5道尔顿的肽的含量是,如40-60%,而游离氨基酸由于它们的苦味,比例优选尽可能低的。尤其适合的是具有如Terheggen-Lagro等.(BMC Pediatrics(BMC儿科)(2002)),2:10)中所述肽长度分布的水解产物。
考虑到紧密连接的最佳闭合和/或预防不希望的肠的渗透性(从而患变态反应的风险增加),此外,可以添加一种或多种非必需氨基酸以提供对此的额外支持。为此,凭借申请人在WO01/58283,NL-1025900和NL-1027262中所述,尤其适合的有谷氨酰胺、谷氨酸、精氨酸和脯氨酸。这里,谷氨酸优于谷氨酰胺,因为谷氨酰胺典型地降低产品的稳定性,而且在肠的酶催化水解之后,还有助于不希望有的氨负载。
按上文规定的,深度水解的酪蛋白水解产物中不存在变应原性的肽,不再包含或几乎没有任何耐受性-诱导肽。为了全部或部分地“修复”耐受性-诱导性质,根据本发明所述组合物,除益生菌之外,还包含耐受性-诱导乳蛋白,如以乳蛋白或乳清蛋白水解产物的形式存在。当生物负载有抗原性的表位时,耐受性诱导典型地在诱导和维持平衡的免疫系统中显示。这例如,用T-细胞平衡表示,如T-辅助细胞的相对量(Th1、Th2和Th3细胞)。
优选地,耐受性-诱导乳蛋白为低-乳脂部分水解的乳清蛋白水解产物。尤其是,乳清蛋白水解产物富含或来自α-乳白蛋白-丰富的乳清蛋白。适宜的乳清蛋白水解产物具有如可以在约5-25%之间变化的水解(DH)度。这还导致该组合物的氨基酸模式变得更类似于人乳。
作为碳水化合物来源,可以使用通常用于儿童食品配方的任何种类的碳水化合物,或不同碳水化合物的混合物。适宜的碳水化合物来源有二糖如乳糖和蔗糖、单糖如葡萄糖、以及麦芽糖糊精、淀粉和具有益生元效果的碳水化合物来源。
根据本发明所述的组合物中的脂质来源可以是适用于儿童食品的任何种类的脂质或脂质的联合。适宜的脂质来源的实例是甘油三酯、甘油二酯和甘油单酯、磷脂、鞘脂类、脂肪酸,以及它们的酯或盐。脂质可以具有动物、植物、微生物来源或合成来源。特别是多不饱和脂肪酸如γ亚麻酸(GLA)、二聚γ亚麻酸(DHGLA)、花生四烯酸(AA)、十八碳四烯酸(SA)、二十碳五烯酸(EPA)、二十二碳六烯酸(DHA)、二十二碳五烯酸(DPA)和共轭亚油酸(CLA)。CLA对抵抗儿童中的湿疹和呼吸性疾病有重要保护作用。尤其包括CLA的顺式-9、反式-11和顺式-12异构体。AA可能被添加于用于最适耐受性诱导的组合物中。
此外,该组合物可以包含一种或多种常用的微量元素,如维生素、抗氧化剂、矿物质、游离氨基酸、核苷酸、氨基乙磺酸、肉碱和多胺。适宜的抗氧化剂如BHT、抗坏血酸棕榈酸酯、生育酚、α和β胡萝卜素、叶黄素、玉米黄素、番茄红素和磷脂。
在一个实施方案中,该组合物涉及一种适合于婴儿的食品或食品添加物。在一个特定形式中,其涉及一种针对最大6个月婴儿的完全婴儿食品。另一种特定形式涉及一种适合于6个月以上婴儿的(改进型)婴儿食品。该组合物蛋白质含量典型地少于3.5克/100千卡。在另一个的具体情形中,其涉及一种适合1-3岁年龄组儿童的成长乳。在另外一个特定的情形中,其涉及一种适合于3-6岁年龄组儿童的成长乳。在另一个特定情形中,其涉及一种适合于3-10岁年龄组儿童的膳食乳(dietary milk)和/或产品,或适合于10-20岁年龄组少年,适合于20-65岁成年人或65-110岁老年人的膳食乳和/或产品。
如上文所述,本发明尤其预期提供一种低变应原的组合物,从长期来看,适于对反刍动物乳脂敏感的儿童。例如,对于患有IRD的儿童,对其长期使用该乳脂导致脂肪组织特别是神经组织中的植烷酸的累积。
乳脂中的植烷酸是来自叶绿素的具有支链的C20脂肪酸,其由食草或食用经提取的粗饲料的反刍动物吸收。由于发生在过氧化物酶体中的植烷酸的降解障碍,比如由于一种或多种酶缺乏或无活性和/或缺乏或缺少过氧化物酶体,植烷酸在体内堆积。
这个问题特别在患有雷弗素姆病,一种过氧化物酶体代谢疾病的患者中是已知。在雷弗素姆病的婴儿型(又名“植烷酸蓄积病”(PASD))中,由于缺乏过氧化物酶体导致血液和组织中不同的脂肪酸堆积。最初的症状在出生时就存在。这些症状为智力下降、容貌略微异常、耳聋、骨质疏松症和生长缓慢。视网膜的损害引发夜盲症和视力日益下降(色素性视网膜炎)。肝脏增大、血液中胆固醇含量提升(高胆固醇血症)。对于婴儿型的雷弗素姆病,没有治愈的可能。雷弗素姆病的治疗由严格遵循不含植烷酸的饮食组成,其目的在于尽可能减轻症状。
在一个具体实施方案中,本发明提供一种组合物,其适合作为患有植烷酸代谢病如婴儿型雷弗素姆病的儿童的食品或有疗效的食品添加物。所述“IRD组合物”包含低-植烷酸脂质来源、碳水化合物来源和具有最高为3000道尔顿的肽的非-变应原的酪蛋白水解产物,其特征在于该组合物包含至少一种摄入身体后会诱发对乳蛋白耐受性的产乳酸益生菌菌株和/或包含至少一种可减少氨负荷的产乳酸益生菌菌株。优选地,该脂质来源为不含植烷酸。该组合物包含如最多0.1wt.%,优选至多0.05wt.%,更优选至多0.01wt.%的含植烷酸的(牛乳)脂肪。
已经显示,雷弗素姆病患者除植烷酸累积外,在他们的循环中还含有低含量的二十二碳六烯酸(DHA)和花生四烯酸(AA)(Moser等,Neurochem.Res.(神经化学研究)1999,187-197)。因此,推荐通过食品补充DHA和AA,尤其是在儿童中。为此,IRD组合物优选包含DHA和/或AA,更优选包含DHA和AA两者。由于DHA和AA对氧化作用敏感,这些长链多不饱和脂肪酸优选与抗氧化剂联合使用于根据本发明所述组合物中。
本发明还提供一种如本发明所述的食品或治疗组合物的用途,其用于治疗或预防与对反刍动物乳蛋白质的变态反应有关的症状。所制备的食品或组合物尤其适合长期使用,优选至少几个月时间。
与对反刍动物乳蛋白的变态反应有关的症状各种各样,尤其包括肠壁紧密连接闭合延缓、肠菌群失调和/或血液尿素水平提升。
由于本发明组合物的增加的营养价值,故其能够有利地用于改善儿童的生长,特别适合作为用于具有对反刍动物乳蛋白变态反应儿童的(长期)治疗剂或作为用于发展所述变态反应风险增加的儿童的(长期)预防剂。
此外,由于使用该组合物,具有变态反应(风险)儿童的缓解百分比可能提高。缓解百分比意思指:随长期使用消除的变态反应,表示为被监测的“问题儿童”的百分比。作为该参数的参考点,实际上认为,大多数母乳喂养的婴儿最终消除变态反应,第一年约为50%,第二年约70%,第三年约85%。使用本发明所述的组合物,第一年后的缓解百分比可以至少提高5%,优选地至少10%。
本发明所述的非变应原组合物可对氨负荷、肠壁闭合、病原体吸附肠壁的预防和/或肠菌群修复具有良好的作用,因此,其尤其适用于有变态反应家族病史的儿童,即发展对乳蛋白变态反应的风险增加的儿童长期预防使用。
本发明的另一方面提供保藏号为ATCC 27536的乳双歧杆菌菌株和保藏号为ATCC 55544的类干酪乳杆菌菌株的组合用于制备组合物的用途,所述组合物用于预防或治疗儿童中呼吸性疾病、胃肠感染或症状、以及眼睛和/或耳朵感染、皮肤感染、内和/或外生殖器感染以及泌尿系统感染,尤其是直到12个月大的儿童,如1-6个月,还有1-10岁的儿童、10-20岁的少年、20-65岁的成年人和65-110岁的老年人。本发明还提供一种用于治疗疾病的方法,包括施用含有有效量适合于治疗感染如呼吸性疾病的预防或治疗组合物的组合物。
本发明还提供一种保藏号为ATCC 27536的乳双歧杆菌菌株和保藏号为ATCC 55544的类干酪乳杆菌菌株的混合物。这些菌株的相对比例,如在10∶1-1∶10之间,优选3∶1-1∶3,如2∶1-1∶2,更优选约1∶1,以菌落形成单位表示。任选地,该混合物包括其他的(益生菌)微生物。该混合物还可以包含可食载体物质,优选地粉末状载体物质如麦芽糖糊精。由上述可知,本发明的益生菌混合物可以有利地用作食品添加物。在一个具体实施方案中,本发明提供一种包含保藏号为ATCC 27536的乳双歧杆菌菌株和保藏号为ATCC 55544的类干酪乳杆菌菌株的食品添加物,其相对比例约为1∶1,用粉末状载体物质稀释。食品添加物如用于制备食品,随着正常摄入该产品,摄取的这些菌株总量在103-1010cfu之间。这可以用来预防和治疗人体内部和人体上的感染。
本发明基于以下实施例举例说明。
实施例:
实施例1通过深度水解的酪蛋白水解产物刺激产乳酸益生菌的生长
从适合生长的基本培养基开始,研究非变应原深度水解的酪蛋白水解产物是否对合适的产乳酸益生菌的生长有促进作用。基本培养基每升包含:
35g的乳糖,25g的醋酸钠,954mg的咪唑,100mg的L-天冬酰胺,200mg的L-胱氨酸,200mg的DL-色氨酸,10mg的尿嘧啶,10mg的鸟嘌呤,10mg腺嘌呤,10mg黄嘌呤,200mg丙氨酸,10mg氯化钠,200mg核黄素,200mg盐酸硫胺,10微克叶酸,600微克烟酸,1.2mg吡多胺.2HCl,200微克泛酸钙,10mg对氨基苯甲酸,5微克生物素,21g L-氨基酸Sigma LAA21,10ml盐溶液。
该酪蛋白水解产物是BMC Pediatrics(儿科)2002(2)10公开的分子量和肽长度分布图的类型。
对于优选菌株类干酪乳杆菌ATCC-55544和乳双歧杆菌ATCC-27536,确定了从上述酪蛋白水解产物起始,对生长明显的益生元作用。
实施例2 适合于遭受变态反应或发展变态反应风险增强的婴儿和儿童的食品或 治疗剂的基本处方
以深度水解酪蛋白、葡萄糖浆、麦芽糖糊精、植物油、精氨酸和微量成分为基础制备食品,此外所述食品富含益生菌类干酪乳杆菌ATCC-55544和乳双歧杆菌ATCC-27536。
酪蛋白水解产物中肽最大分子量为2.5kDa。根据实施例1的试验,该酪蛋白水解产物刺激两种益生菌的生长。
该食品包含两种益生菌的2×107菌落形成单位/克粉末。
粉末状益生菌水解产物食品的组成为每一百克粉末(单位都为克):
酪蛋白水解产物 12
脂肪(植物) 27
葡萄糖浆+麦芽糖糊精 55.7
L-精氨酸 0.3
微量成分 2
流体 3
实施例3婴儿试验结果
用实施例2食品进行对比试验,在有和没有添加益生菌的情况下,用于患有变态反应的婴儿,结果显示益生菌对一般抗性、免疫状况和呼吸性疾病有良好的效果。
该试验包括119位研究开始时为1.4-6个月(平均4.2个月)龄的婴儿:55%为男性。
该组被随机分成益生菌组和安慰剂组。在12个月期间,安慰剂组喂养已知的婴儿食品Friso 1 Allergy Care(变态反应护理)(Friesland Nutrition(弗里斯兰营养))。该益生菌组喂养补充有类干酪乳杆菌CRL431和乳双歧杆菌Bb-12(107cfu/株/克配方)的Friso 1 Allergy Care(变态反应护理)。
12个月之后,观察CD3+淋巴细胞的明显变化,判定益生菌组是有利的。在安慰剂组中,在6个月的时期内,相比益生菌组发展了更多的呼吸性疾病。
富含两种培养物的食品被有利地推荐且用于有变态反应家族病史儿童的预防没有任何特别的风险。
实施例4 低变应原的基本配方
制备100克适用于IRD儿童或婴儿的水解产物食品,包含类干酪乳杆菌ATCC-55544+乳双歧杆菌ATCC-27536,以及下列组分(均为克):
酪蛋白水解产物 12
植物+动物+微生物+合成脂质 27
(包含0.04%AA+0.02%DHA+0.3%CLA)
牛乳脂肪 0
葡萄糖浆+麦芽糖糊精 55.7
精氨酸 0.3
微量成分 2
流体 3
蛋白质当量%(计算的;Nx6.25) 11.7
牛乳脂肪%(计算的) <0.06
实施例5以乳蛋白为基础的预防性婴儿食品或营养品
制备按表1所示标准配方(Ffiso 1)。该配方包含非-水解乳蛋白,其中酪蛋白与乳清蛋白的重量比为40∶60,此外,还包含来源于乳脂之外来源的脂肪、碳水化合物、益生元纤维(GOS)、维生素、矿物质和核苷酸。益生菌混合物按照实施例3制备。该益生菌按表2规定的浓度添加到Friso 1中
表1:Friso 1组成(每100ml)
表2:益生菌的量以每克粉末形式配方中菌落形成单位(cfu)表示添加于Friso1中。
实施例6:食品添加物
制备类干酪乳杆菌类干酪亚种(Lactobacillus paracasei subspecies paracaseiCRL431(约1×1013CFU/g)和动物双歧杆菌乳亚种(Bifidobacterium animalissubspecies lactis)BB12(约1×1013CFU/g)(来自CHR Hansen,Copenhagen,丹麦)为1∶1比率的混合物。接着益生菌混合物以麦芽糖糊精作为载体物质或载体被稀释(如1∶4但取决于其使用)。因此产生的益生菌食品添加物可以加入用于人或动物的食品中,特别地,加入用于0-6,6-12个月婴儿,1-3,3-6和1-10岁儿童,10-20岁少年,20-65岁成年人,65-110岁老人年龄组的人,用于男性和女性的食品中。
实施例7:益生菌混合物对抵抗感染的效果
除母乳喂养作为参照组外,从出生起,包括两组健康的儿童,一组获得常规起始食品Friso 1(对比处方),另一组则为Friso 1+益生菌。Friso 1婴儿食品的组成如表1所述。添加到Friso 1中的益生菌(类干酪乳杆菌类干酪亚种CRL431和动物双歧杆菌乳亚种BB 12)的浓度如表2所规定。该内含物为随机化的且用双盲法介入。从婴儿出生后1周起观察6个月。在介入期间,收集儿童的antropometric信息,调查粪便的微生物菌群组成,以及在儿童中使用的抗生素。此外,调查儿童中发现感染的性质、等级和严重程度。
已经发现,类干酪乳杆菌类干酪亚种CRL431和动物双歧杆菌乳亚种BB 12的益生菌混合物使用安全,并观察到其对感染有积极作用。
Claims (22)
1、一种组合物,优选地婴儿食品,包含脂质来源,碳水化合物来源和含有最大为3000道尔顿的肽的低-变应原的酪蛋白水解产物,其特征在于所述组合物还包含保藏号为ATCC 27536的乳双歧杆菌(B.lactis)菌株和保藏号为ATCC 55544的类干酪乳杆菌(L.casei)菌株。
2、如权利要求1所述的组合物,其中酪蛋白水解产物是一种非变应原的低脂肪深度水解酪蛋白水解产物。
3、一种组合物,包含脂质来源、碳水化合物来源和蛋白质来源,其特征在于所述组合物还包含保藏号为ATCC 27536的乳双歧杆菌菌株和保藏号为ATCC55544的类干酪乳杆菌菌株,其中所述组合物不是权利要求1或2所述的组合物。
4、如权利要求3所述的组合物,其中蛋白质来源选自由乳蛋白、脱脂乳、酪蛋白、脱盐或未脱盐乳清、乳清蛋白、富含α-乳白蛋白的(乳清)蛋白、乳铁蛋白和部分水解的乳蛋白、植物蛋白以及它们的水解产物组成的组。
5、根据权利要求1-4中任一项所述的组合物,其中所述组合物包含103-109,优选最少106-107个菌落形成单位/细菌菌株/克干燥产品。
6、根据权利要求1-5中任一项所述的组合物,其中所述组合物包含耐受性-诱导乳蛋白或乳蛋白水解产物。
7、根据权利要求6所述的组合物,其中所述乳蛋白(水解产物)为乳清蛋白(水解产物),优选低-乳脂α-乳白蛋白水解产物。
8、根据权利要求1-7中任一项所述的组合物,其中所述组合物包含有助于氨处理的添加组分,优选精氨酸。
9、根据权利要求1-8中任一项所述的组合物,其中所述脂质来源涉及一种或多种选自甘油三酯、甘油二酯和甘油单酯、磷脂和鞘脂类、脂肪酸、以及它们的酯或盐的组分。
10、根据权利要求1-9中任一项所述的组合物,其中所述组合物包含至少一种多不饱和脂肪酸,优选地选自γ亚麻酸(GLA),二聚γ亚麻酸(DHGLA),花生四烯酸(AA),十八碳四烯酸(SA),二十碳五烯酸(EPA),二十二碳六烯酸(DHA),二十二碳五烯酸(DPA)和共轭亚油酸(CLA),更优选至少DHA和AA。
11、根据权利要求1-10中任一项所述的组合物,其包括益生元,优选选自短链或长链果糖-寡糖和/或半乳糖-寡糖、菊粉、含岩藻糖寡糖、β聚糖、角豆粉、树胶、果胶、唾液酸寡糖、唾液酸乳糖、短链或长链半乳聚糖和核苷酸。
12、根据权利要求1-11中任一项所述的组合物,包括至少一种乳双歧杆菌菌株和一种或多种用于该菌株的益生元的组合,所述益生元优选地选自核苷酸、唾液酸寡糖、果糖寡糖(FOS)、葡萄糖寡糖(GOS)和唾液酸乳糖。
13、根据权利要求1-12中任一项所述的组合物,其中所述组合物包含以最终组合物为基础,最大为0.1wt.%,优选最大为0.05wt.%,更优选最大为0.01wt.%的含植烷酸的脂肪。
14、权利要求1或2,和从属于权利要求1或2的权利要求5-13所述组合物作为治疗或预防反刍动物乳蛋白质变态反应相关症状的食品或治疗组合物的用途。
15、权利要求13所述的组合物用于制备食品或治疗组合物的用途,所述组合物用于患有植烷酸代谢疾病的婴儿或儿童,优选地用于患有雷弗素姆病的儿童。
16、用权利要求1-13中任一项所述的组合物作为治疗或预防儿童呼吸性疾病的食品或治疗组合物的用途。
17、保藏号为ATCC 27536的乳双歧杆菌菌株与保藏号为ATCC 55544的类干酪乳杆菌菌株联合制备预防或治疗组合物的用途,所述组合物用于预防或治疗胃肠道、气道、窦腔、耳朵或耳腔、眼睛、泌尿系统、生殖器内部和外表面、人皮肤的普通传染性疾病,尤其是婴儿和儿童的呼吸性疾病。
18、权利要求14-17任一项所述的用途,其中所述食品或组合物意欲长期使用,优选至少3-6个月时间。
19、保藏号为ATCC 27536的乳双歧杆菌菌株和保藏号为ATCC 55544的类干酪乳杆菌菌株的混合物。
20、如权利要求19所述的混合物,其中所述菌株相对比率为3∶1-1∶3之间,优选2∶1-1∶2,更优选约1∶1,以菌落形成单位表示。
21、如权利要求19或20所述的混合物,还包含可食载体物质,优选粉末状载体物质。
22、权利要求19-21中任一项所述的混合物作为食品添加物的用途。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NL1032840 | 2006-11-09 | ||
NL1032840A NL1032840C2 (nl) | 2006-11-09 | 2006-11-09 | Probiotische hydrolysaatvoeding voor kinderen. |
Publications (1)
Publication Number | Publication Date |
---|---|
CN101594789A true CN101594789A (zh) | 2009-12-02 |
Family
ID=38190812
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CNA2007800417554A Pending CN101594789A (zh) | 2006-11-09 | 2007-11-09 | 益生菌(婴儿)食品 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20100047393A1 (zh) |
EP (1) | EP2094114A1 (zh) |
CN (1) | CN101594789A (zh) |
MX (1) | MX2009004945A (zh) |
NL (1) | NL1032840C2 (zh) |
RU (1) | RU2009121781A (zh) |
WO (1) | WO2008056983A1 (zh) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102724886A (zh) * | 2009-10-29 | 2012-10-10 | 雀巢产品技术援助有限公司 | 包含乳铁蛋白和益生菌的营养组合物及其套盒 |
CN102762115A (zh) * | 2010-02-24 | 2012-10-31 | 美赞臣营养品公司 | 供给营养素的制剂和方法 |
CN103220921A (zh) * | 2010-10-15 | 2013-07-24 | 科.汉森有限公司 | 免疫佐剂 |
CN103391783A (zh) * | 2010-12-31 | 2013-11-13 | 雅培制药有限公司 | 使用人乳寡糖改善呼吸道健康的方法 |
CN103442717A (zh) * | 2010-11-23 | 2013-12-11 | 雀巢产品技术援助有限公司 | 用于治疗皮肤疾病的包含水解的蛋白质和寡糖的组合物 |
CN104168905A (zh) * | 2011-06-10 | 2014-11-26 | 杜邦营养生物科学有限公司 | 使用乳双歧杆菌bl-04治疗呼吸道疾病 |
US9049881B2 (en) | 2009-08-18 | 2015-06-09 | Nestec S.A. | Nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children |
TWI584736B (zh) * | 2009-12-04 | 2017-06-01 | 美強生營養品美國控股公司 | 包含供誘導耐受性用之含有牛乳肽的水解產物及/或衍生自牛乳肽之肽類的營養配方 |
CN106923345A (zh) * | 2017-03-19 | 2017-07-07 | 北京罗诺强施医药技术研发中心有限公司 | 稳定的益生菌组合物 |
CN107050063A (zh) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | 治疗过敏体质的乳酸菌组合物及其制备方法 |
US10369164B2 (en) | 2010-12-31 | 2019-08-06 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US10813940B2 (en) | 2010-12-31 | 2020-10-27 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
CN111869733A (zh) * | 2020-07-31 | 2020-11-03 | 贝因美股份有限公司 | 一种低敏乳蛋白功能因子组合物其应用和一种低敏儿童配方奶粉 |
Families Citing this family (40)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8075934B2 (en) | 2008-10-24 | 2011-12-13 | Mead Johnson Nutrition Company | Nutritional composition with improved digestibility |
US8968721B2 (en) | 2005-12-28 | 2015-03-03 | Advanced Bionutrition Corporation | Delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same |
WO2007079147A2 (en) | 2005-12-28 | 2007-07-12 | Advanced Bionutrition Corporation | A delivery vehicle for probiotic bacteria comprising a dry matrix of polysaccharides, saccharides and polyols in a glass form and methods of making same |
EP2117354B1 (en) | 2006-12-18 | 2018-08-08 | Advanced BioNutrition Corp. | A dry food product containing live probiotic |
US20110212224A1 (en) * | 2008-11-21 | 2011-09-01 | Cruz Serrano Jose Antonio | Method for obtaining a mixture of probiotics, prebiotics nutrients with synergistic symbiotic action |
US9623094B2 (en) | 2009-03-27 | 2017-04-18 | Advanced Bionutrition Corporation | Microparticulated vaccines for the oral or nasal vaccination and boostering of animals including fish |
EP2419114B2 (en) | 2009-05-01 | 2019-02-27 | UAS Laboratories LLC | Bacterial compositions for prophylaxis and treatment of degenerative disease |
IT1394437B1 (it) * | 2009-05-07 | 2012-06-15 | Farmagens Health Care Srl | Composizione nutraceutica contenente proteine di carne di agnello e/o pollo con batteri probiotici, suo procedimento di preparazione e uso nell'alimentazione umana. |
EP2435554B1 (en) | 2009-05-26 | 2017-07-26 | Advanced Bionutrition Corporation | Stable dry powder composition comprising biologically active microorganisms and/or bioactive materials and methods of making |
EP2464240A1 (en) * | 2009-08-10 | 2012-06-20 | K.D. Pharma Bexbach GMBH | Phytanic acid fractionation process, fatty acid products and use thereof |
US20110070334A1 (en) | 2009-09-20 | 2011-03-24 | Nagendra Rangavajla | Probiotic Stabilization |
US8834951B2 (en) | 2010-01-28 | 2014-09-16 | Advanced Bionutrition Corporation | Dry glassy composition comprising a bioactive material |
US9504750B2 (en) | 2010-01-28 | 2016-11-29 | Advanced Bionutrition Corporation | Stabilizing composition for biological materials |
NL2004201C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides to modulate the immune system. |
NL2004200C2 (en) | 2010-02-05 | 2011-08-08 | Friesland Brands Bv | Use of sialyl oligosaccharides in weight management. |
WO2011150949A1 (en) | 2010-06-04 | 2011-12-08 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
EP3508075B1 (en) * | 2010-06-04 | 2022-10-26 | N.V. Nutricia | Non-digestible oligosaccharides for oral induction of tolerance against dietary proteins |
DK2603100T3 (en) | 2010-08-13 | 2018-08-06 | Advanced Bionutrition Corp | DRY STABILIZING COMPOSITION FOR STORAGE OF BIOLOGICAL MATERIALS |
WO2012044155A1 (en) | 2010-09-28 | 2012-04-05 | N.V. Nutricia | Fat composition for programming immune response |
MY162776A (en) | 2010-12-29 | 2017-07-14 | Abbott Lab | Nutritional products including monoglycerides and fatty acids |
MY180910A (en) | 2010-12-31 | 2020-12-11 | Abbott Lab | Methods for reducing the incidence of oxidative stress using human milk oligosaccharides, vitamin c and anti-inflammatory agents |
SG10202110501RA (en) | 2010-12-31 | 2021-11-29 | Abbott Lab | Methods For Decreasing The Incidence Of Necrotizing Enterocolitis In Infants, Toddlers, Or Children Using Human Milk Oligosaccharides |
CN103402376A (zh) | 2010-12-31 | 2013-11-20 | 雅培制药有限公司 | 促进有益细菌生长的中性人乳寡糖 |
EP2658548B1 (en) | 2010-12-31 | 2018-02-21 | Abbott Laboratories | Human milk oligosaccharides for modulating inflammation |
ES2657744T3 (es) | 2011-07-22 | 2018-03-06 | Abbott Laboratories | Galactoligosacáridos para prevenir lesiones y/o promover la curación del tracto gastrointestinal |
US10639319B2 (en) | 2011-08-29 | 2020-05-05 | Abbott Laboratories | Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract |
EP2604123A1 (en) | 2011-12-15 | 2013-06-19 | Friesland Brands B.V. | Method and nutritional compositions for the treatment of diarrhea. |
US9138455B2 (en) | 2013-03-15 | 2015-09-22 | Mead Johnson Nutrition Company | Activating adiponectin by casein hydrolysate |
US8889633B2 (en) | 2013-03-15 | 2014-11-18 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component with anti-inflammatory properties and uses thereof |
US9352020B2 (en) | 2013-03-15 | 2016-05-31 | Mead Johnson Nutrition Company | Reducing proinflammatory response |
US9289461B2 (en) | 2013-03-15 | 2016-03-22 | Mead Johnson Nutrition Company | Reducing the risk of autoimmune disease |
US9345727B2 (en) * | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional compositions containing a peptide component and uses thereof |
US9345741B2 (en) | 2013-03-15 | 2016-05-24 | Mead Johnson Nutrition Company | Nutritional composition containing a peptide component with adiponectin simulating properties and uses thereof |
US10568896B2 (en) | 2013-11-19 | 2020-02-25 | Abbott Laboratories | Methods for preventing or mitigating acute allergic responses using human milk oligosaccharides |
AU2014363469B2 (en) | 2013-12-13 | 2018-08-09 | Société des Produits Nestlé S.A. | Use of a sweet whey containing infant formula for promoting the postnatal neuronal development of the infant gastrointestinal tract, and the establishment of the intestinal functions that it controls |
MY194231A (en) | 2015-07-29 | 2022-11-23 | Advanced Bionutrition Corp | Stable dry probiotic compositions for special dietary uses |
US11197917B2 (en) | 2017-12-01 | 2021-12-14 | ByHeart, Inc. | Formulations for nutritional support in subjects in need thereof |
FR3083981B1 (fr) * | 2018-07-20 | 2021-01-15 | Semiocare Sas | Compositions a usage cosmetique et dermatologique |
AU2022218203A1 (en) * | 2021-02-08 | 2023-08-24 | Capsugel Belgium Nv | Extended release vitamin c and manufacturing thereof |
CN113317494A (zh) * | 2021-06-03 | 2021-08-31 | 浙江益元素食品有限公司 | 一种全营养配方粉及其制备方法和应用 |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08511533A (ja) * | 1993-06-09 | 1996-12-03 | マーテック・バイオサイエンスィズ・コーポレーション | 神経学的障害の治療に有用な方法および医薬用組成物 |
ES2247746T3 (es) * | 1999-04-29 | 2006-03-01 | Societe Des Produits Nestle S.A. | Formula para lactantes, que contiene proteina de suero lacteo dulce. |
US20040105848A1 (en) * | 1999-04-30 | 2004-06-03 | Natarajan Ranganathan | Enteric dialysis compositions and methods |
NL1014380C2 (nl) * | 2000-02-14 | 2001-08-15 | Friesland Brands Bv | Darmwandversterkend voedingsmiddel. |
US20030017192A1 (en) * | 2001-06-19 | 2003-01-23 | Hanny Kanafani | Process for producing extended shelf-life ready-to-use milk compositions containing probiotics |
EP1364586A1 (en) * | 2002-05-24 | 2003-11-26 | Nestec S.A. | Probiotics and oral tolerance |
DE602004030567D1 (de) * | 2003-06-23 | 2011-01-27 | Nestec Sa | Säuglingsnährpräparat oder folgemilch |
WO2004112509A2 (en) * | 2003-06-23 | 2004-12-29 | Nestec S.A. | Nutritional formula for optimal gut barrier function |
NL1027262C2 (nl) * | 2004-04-08 | 2005-10-13 | Friesland Brands Bv | Toepassing van met proline verrijkte samenstellingen voor het bereiden van voedingsmiddelen en therapeutische samenstellingen. |
EP1629850B2 (en) * | 2004-08-24 | 2013-05-22 | N.V. Nutricia | Nutritional composition comprising indigestible transgalactooligosaccharides and digestible galactose saccharides |
US20060233915A1 (en) * | 2005-04-15 | 2006-10-19 | Bristol-Myers Squibb Company | Liquid nutritional product to supplement human milk |
-
2006
- 2006-11-09 NL NL1032840A patent/NL1032840C2/nl not_active IP Right Cessation
-
2007
- 2007-11-09 EP EP07834678A patent/EP2094114A1/en not_active Withdrawn
- 2007-11-09 MX MX2009004945A patent/MX2009004945A/es not_active Application Discontinuation
- 2007-11-09 WO PCT/NL2007/050549 patent/WO2008056983A1/en active Application Filing
- 2007-11-09 US US12/514,374 patent/US20100047393A1/en not_active Abandoned
- 2007-11-09 RU RU2009121781/10A patent/RU2009121781A/ru not_active Application Discontinuation
- 2007-11-09 CN CNA2007800417554A patent/CN101594789A/zh active Pending
Cited By (25)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9049881B2 (en) | 2009-08-18 | 2015-06-09 | Nestec S.A. | Nutritional composition comprising lactococcus strains and reducing allergy symptoms, especially in infants and children |
CN102724886A (zh) * | 2009-10-29 | 2012-10-10 | 雀巢产品技术援助有限公司 | 包含乳铁蛋白和益生菌的营养组合物及其套盒 |
TWI584736B (zh) * | 2009-12-04 | 2017-06-01 | 美強生營養品美國控股公司 | 包含供誘導耐受性用之含有牛乳肽的水解產物及/或衍生自牛乳肽之肽類的營養配方 |
CN102762115A (zh) * | 2010-02-24 | 2012-10-31 | 美赞臣营养品公司 | 供给营养素的制剂和方法 |
CN105288616B (zh) * | 2010-10-15 | 2018-10-19 | 科.汉森有限公司 | 免疫佐剂 |
CN103220921A (zh) * | 2010-10-15 | 2013-07-24 | 科.汉森有限公司 | 免疫佐剂 |
CN103220921B (zh) * | 2010-10-15 | 2015-12-16 | 科.汉森有限公司 | 免疫佐剂 |
CN105288616A (zh) * | 2010-10-15 | 2016-02-03 | 科.汉森有限公司 | 免疫佐剂 |
CN103442717A (zh) * | 2010-11-23 | 2013-12-11 | 雀巢产品技术援助有限公司 | 用于治疗皮肤疾病的包含水解的蛋白质和寡糖的组合物 |
US11524018B2 (en) | 2010-12-31 | 2022-12-13 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11464793B2 (en) | 2010-12-31 | 2022-10-11 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11975014B2 (en) | 2010-12-31 | 2024-05-07 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
CN103391783A (zh) * | 2010-12-31 | 2013-11-13 | 雅培制药有限公司 | 使用人乳寡糖改善呼吸道健康的方法 |
CN109620834A (zh) * | 2010-12-31 | 2019-04-16 | 雅培制药有限公司 | 使用人乳寡糖改善呼吸道健康的方法 |
US10369164B2 (en) | 2010-12-31 | 2019-08-06 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US10813940B2 (en) | 2010-12-31 | 2020-10-27 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US11701376B2 (en) | 2010-12-31 | 2023-07-18 | Abbott Laboratories | Nutritional compositions comprising human milk oligosaccharides and nucleotides and uses thereof for treating and/or preventing enteric viral infection |
US10973837B2 (en) | 2010-12-31 | 2021-04-13 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11197875B2 (en) | 2010-12-31 | 2021-12-14 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11654156B2 (en) | 2010-12-31 | 2023-05-23 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
US11633412B2 (en) | 2010-12-31 | 2023-04-25 | Abbott Laboratories | Nutritional formulations including human milk oligosaccharides and antioxidants and uses thereof |
CN104168905A (zh) * | 2011-06-10 | 2014-11-26 | 杜邦营养生物科学有限公司 | 使用乳双歧杆菌bl-04治疗呼吸道疾病 |
CN107050063A (zh) * | 2016-11-08 | 2017-08-18 | 江西益盟科技有限公司 | 治疗过敏体质的乳酸菌组合物及其制备方法 |
CN106923345A (zh) * | 2017-03-19 | 2017-07-07 | 北京罗诺强施医药技术研发中心有限公司 | 稳定的益生菌组合物 |
CN111869733A (zh) * | 2020-07-31 | 2020-11-03 | 贝因美股份有限公司 | 一种低敏乳蛋白功能因子组合物其应用和一种低敏儿童配方奶粉 |
Also Published As
Publication number | Publication date |
---|---|
MX2009004945A (es) | 2009-08-18 |
WO2008056983A1 (en) | 2008-05-15 |
RU2009121781A (ru) | 2010-12-20 |
EP2094114A1 (en) | 2009-09-02 |
NL1032840C2 (nl) | 2008-05-13 |
US20100047393A1 (en) | 2010-02-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101594789A (zh) | 益生菌(婴儿)食品 | |
RU2506824C2 (ru) | Питательная композиция со свободными аминокислотами и структурированными липидами | |
ES2725464T3 (es) | Sistema de fórmula infantil con niveles adaptativos de oligosacáridos de leche humana (OLH) | |
ES2314461T3 (es) | Composicion simbiotica para bebes. | |
ES2702631T3 (es) | Composición nutricional con prebióticos y probióticos | |
AU2012260945B2 (en) | Milk oligosaccharide-galactooligosaccharide composition for infant formula containing the soluble oligosaccharide fraction present in milk, and having a low level of monosaccharides, and a process to produce the composition | |
RU2491080C2 (ru) | Снижение риска диареи | |
CN1863463B (zh) | 用于促进肠道屏障成熟的营养组合物 | |
ES2442344T3 (es) | Probióticos para incrementar la secreción de IgA en bebés nacidos por cesárea | |
AU2005228768B2 (en) | Antibacterial compositions | |
MX2008011450A (es) | Mezcla simbiotica. | |
ES2320988T3 (es) | Metodo para prevenir o aliviar los sintomas de malabsorcion a traves del tracto gastrointestinal. | |
AU2020257046B2 (en) | Nutritional compositions comprising a casein hydrolysate, as well as dietary butyrate and/or a compound for stimulating formation of endogenous butyrate | |
TW201242518A (en) | Oligosaccharide mixture and food product comprising this mixture, especially infant formula | |
EP2440073A1 (en) | Synergistic mixture of beta-galacto-oligosaccharides with beta-1,3 and beta-1,4/1,6 linkages | |
HUE031289T2 (hu) | Fermentált bébitápszer emészthetetlen oligoszacharidokkal | |
CN104394714A (zh) | 腹腔疾病和食物过敏的饮食管理 | |
CN110996686A (zh) | 含有人乳低聚糖的营养组合物及其用途 | |
CN109890222A (zh) | 包含人乳低聚糖的个性化儿科营养产品 | |
HUE026180T2 (en) | Fermented Child Nutrition | |
TW201822650A (zh) | 含有人乳寡糖之營養組成物和彼之用途 | |
WO2011071134A1 (ja) | インフルエンザ感染症の予防組成物 | |
EP3454674B1 (en) | Methods of use of fermented infant formula | |
WO2012078030A1 (en) | Fermented infant formula | |
WO2016018533A1 (en) | Hydrolyzed lactose-containing nutritional compositions and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1138486 Country of ref document: HK |
|
C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20091202 |
|
REG | Reference to a national code |
Ref country code: HK Ref legal event code: WD Ref document number: 1138486 Country of ref document: HK |